Collegium Pharmaceutical, Inc. · NASDAQ:COLL

Collegium Pharmaceutical — Q3 2026 Earnings Presentation

48 slides from Collegium Pharmaceutical's earnings presentation, Nov 5, 2026

  1. Slide 1: Investor Presentation

    Investor Presentation Novemb er 2026 | NA S DAQ : CO LL A commercial-stage biopharmaceutical company focused on improving the lives of people living with serious neurological and pain conditions Actor portrayals

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates,"

  3. Slide 3: Building a Leading, Diversified Biopharmaceutical Company

    2 Building a Leading, Diversified Biopharmaceutical Company BY THE NUMBERS Healthier people. Stronger communities. $840M $458M 2 2026 Product Sales1 2026 Adjusted Current focus areas: EBITDA1,2 ADHD & Pain DIFFERENTIATED MEDICINES 1. This financial data represents the midpoint of 2026 financial guid

  4. Slide 4: Committed to Making a Positive Difference for Patients and Communities

    3 Committed to Making a Positive Difference for Patients and the Communities We Serve Keeping Patients at the Investing in Our Center of Everything We Do People and Communities Delivering differentiated medicines Investing in our people that uniquely serve patient unmet need Fostering an engaging, c

  5. Slide 5: Path to Building a Leading, Diversified Biopharmaceutical Company

    4 Path to Building a Leading, Diversified Biopharmaceutical Company History of becoming the leader in Beginning of responsible pain management diversification strategy 2002 2016 2022 FDA approved Acquired Belbuca®, 2026 Founded to address opioid Xtampza® ER formulated solidifying leadership in Acqui

  6. Slide 6: Collegium's Vision for the Next Phase of Growth

    5 Collegium’s Vision for the Next Phase of Growth FURTHER EXPANSION Product diversification and capital deployment Opportunity NEUROPSYCHIATRY and PEDIATRICS PAIN PORTFOLIO Time Future 5

  7. Slide 7: 2026 Financial Guidance

    6 2026 Financial Guidance 2025 2026 Guidance Actuals YoY Change3 Range2 Product Revenues, Net $781M $825 – 855M +8% JORNAY PM Revenue, Net $149M $190 - 200M +31% AZSTARYS Revenue, Net N/A4 $65 – 75M N/A Adjusted EBITDA1 $460M $445 – 470M Flat 1. Represents a non-GAAP financial measure. Refer to “Non

  8. Slide 8: Strategic Priorities to Drive Value Creation

    7 Strategic Priorities to Drive Value Creation 2026 Strategic Priorities VALUE CREATION Drive further growth for ADHD Portfolio ✓ Grows revenue ✓ Extends longevity Maximize the durability of the ✓ Increases profitability Pain Portfolio ✓ Generates robust cash flows Strategically deploy capital ✓ Div

  9. Slide 9: Successful Track Record of Growth and Strategic Capital Deployment

    8 Successful Track Record of Growth and Strategic Capital Deployment Strong Commercial Execution Robust Financial Results Strategic Capital Deployment Product Revenues, Net1 Adjusted EBITDA1,3 $840M2 $781M $461M $458M2 $631M $401M $567M $367M $464M $266M $272M Share repurchases between 2021 and 2026

  10. Slide 10: Q3 2026 Business Highlights

    9 Q3 2026 Business Highlights1 Accelerated Strong Financial Strategically Commercial Momentum Position Deployed Capital Product Revenues, Net ADHD Portfolio +3% $50M accelerated share repurchase +24% YoY growth $216M program announced in Q3’26 in Q3’26 net revenue $209M $26.5M in Q3’26 net revenue;

  11. Slide 11: Driving Significant Growth in the ADHD Portfolio

    Driving Significant Growth in the ADHD Portfolio Actor portrayals

  12. Slide 12: Overview of U.S. ADHD Market and Key Commercial Dynamics

    11 Overview of U.S. ADHD Market and Key Commercial Dynamics 20251 Commercial Dynamics Total ADHD Market annual prescriptions 1. Large and growing market ~111M 8% CAGR from 2020-2025 Stimulants 2. High patient unmet need annual prescriptions Patients on average try ~3 different ADHD medicines before

  13. Slide 13: Unmet Need Remains Despite Multiple Treatment Options Available

    12 Unmet Need Remains Despite Multiple Treatment Options Available TREATMENT CHALLENGES 1 HCP’s cite all-day symptom control without the Average ADHD patient tries ~3 need for a short-acting stimulant add-on as the most significant challenge 2 different medicines before finding the right treatment o

  14. Slide 14: ADHD Leadership and Strong Brand Fundamentals

    13 ADHD Leadership and Strong Brand Fundamentals Only ADHD stimulant that provides all-day symptom First and only ADHD stimulant treatment with both fast and control that starts immediately upon awakening long-acting medicines in one capsule, delivering rapid, all-day symptom control #1 highest rate

  15. Slide 15: Highly Differentiated Medicine in the ADHD Market

    14 Highly Differentiated Medicine in the ADHD Market • Highly differentiated central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD in people six years of age and older in the U.S. • Only stimulant ADHD medication with once-daily evening dosing that provides symptom c

  16. Slide 16: Highly Differentiated Medicine in the ADHD Market

    15 Highly Differentiated Medicine in the ADHD Market • Highly differentiated central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD in people six years of age and older in the U.S. • Only stimulant ADHD treatment with both an immediate release and prodrug component in

  17. Slide 17: Fastest Growing Stimulant for Treatment of ADHD

    16 Fastest Growing Stimulant for Treatment of ADHD GROWTH STRONG MARKET SHARE IN IN QUARTERLY AND GROWING BRANDED LONG-ACTING PRESCRIPTIONS 1 PRESCRIBER BASE 2 METHYLPHENIDATE MARKET 1 +16% +19% +6.5 Percentage Points 33K 223K 30% 192K 28K 23% Q3'25 Q3'26 Q3'25 Q3'26 Q3'25 Q3'26 1. IQVIA NPA through

  18. Slide 18: AZSTARYS is Well Positioned for Future Growth

    1 17 AZSTARYS is Well Positioned for Future Growth GROWTH IN 2026 REVENUE QUARTERLY OUTLOOK PRESCRIPTIONS1 $65-75M +2% in revenue expected between 190K May 12 and December 31, 2026 187K IP Protection Q3'25 Q3'26 through 2037 Note: AZSTARYS prescriptions declined by ~2% in 2025 prior to Collegium own

  19. Slide 19: 2026 Priorities: Driving Further Growth for ADHD Portfolio

    18 2026 Priorities: Driving Further Growth for ADHD Portfolio • Successfully integrate AZSTARYS into • Increase awareness and adoption with portfolio expanded set of prescribers • Accelerate growth trajectory by • Raise caregiver and patient awareness leveraging established commercial to drive HCP r

  20. Slide 20: Maximizing the Durability of the Pain Portfolio

    Maximizing the Durability of the Pain Portfolio Actor portrayals

  21. Slide 21: The Leader in Responsible Pain Management

    20 The Leader in Responsible Pain Management STRONG BRAND FUNDAMENTALS 1 PAIN PRODUCT REVENUES, NET 2 • Belbuca: +5% +6% +22% • The ONLY long-acting opioid pain medicine that uses $632M +68% $594M buprenorphine buccal film technology $567M • #1 highest rated branded ER opioid in terms of product $46

  22. Slide 22: Strategically Deploying Capital and Creating Shareholder Value

    Strategically Deploying Capital and Creating Shareholder Value Actor portrayals

  23. Slide 23: Track Record of Successful Business Development With Effective Debt Management

    22 Track Record of Successful Business Development Driving Top- and Bottom-Line Growth With Effective Debt Management Acquisitions Financial Impact Nucynta Franchise (2020) Product Revenues, Net1 Adjusted EBITDA1,4 $840M2 $781M BDSI (2022) $631M $461M $458M2 $567M $401M $367M $464M $582M $440M $266M

  24. Slide 24: Commercial Capabilities and Financial Firepower Drive Value Creation

    23 Commercial Capabilities and Financial Firepower Drive Value Creation BUSINESS DEVELOPMENT FRAMEWORK Expertise in Competitive Significant Cash Generation Specialty Markets Robust Revenues Rapid Integration Commercial VALUE Financial High Gross Margins Capabilities CREATION Firepower Securing Broad

  25. Slide 25: Disciplined Business Development Approach

    24 Disciplined Business Development Approach TARGET THERAPEUTIC AREAS ADDITIONAL FEATURES Guiding • Neuropsychiatry and pediatrics • Commercial or near-commercial Framework • Other specialty conditions • Cost efficient sales and marketing for Near-term (case-by-case) requirements BD Efforts • Rare d

  26. Slide 26: Opportunistic Share Repurchases Deliver Value to Shareholders

    25 Opportunistic Share Repurchases Deliver Value to Shareholders1 Returned $272M to Shareholders since 2021 Repurchased 10.7M shares at average price of $24.75 $75M $25M $60M 2021 - 2.2M shares at $19.93 $50M2 $43M $25M 2022 - 1.1M shares at $17.57 $18M $25M 2023 - 3.1M shares at $24.29 $19M $50M $3

  27. Slide 27: Strong IP Management

    Strong IP Management Actor portrayals

  28. Slide 28: Strong IP Management of Patent Protected Portfolio

    27 Strong IP Management of Patent Protected Portfolio 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 March 2032 Lead Growth Driver December 2037 September 2033 2036 Durable Cash Generators January 2027 2032 Projected exclusivity Generics Launched in Q1 2026 Latest patent expiry Aut

  29. Slide 29: Summary

    S a } Tey <@O Collegium. PHARMACEUTICAL

  30. Slide 30: Serving Patients and Creating Value for Shareholders

    29 Serving Patients and Creating Value for Shareholders 2026 STRATEGIC PRIORITIES 1. Drive further growth for the 2. Maximize the durability 3. Strategically deploy capital ADHD Portfolio of the Pain Portfolio • Business Development • Debt repayment • Share repurchases VALUE CREATION Grow Extend Inc

  31. Slide 31: Important Safety Information

    Important Safety Information

  32. Slide 32: Important Safety Information about JORNAY PM

    31 Important Safety Information about JORNAY PM JORNAY PM (methylphenidate HCI extended-release (methylphenidate HCI extended-release capsules) capsules) WARNING: ABUSE, MISUSE, AND ADDICTION JORNAY PM has a high potential for abuse and misuse, which can lead to the development of a substance use di

  33. Slide 33: Important Safety Information about JORNAY PM

    32 Important Safety Information about JORNAY PM JORNAY PM (methylphenidate HCI extended-release (methylphenidate HCI extended-release capsules) capsules) WARNINGS AND PRECAUTIONS JORNAY PM can cause serious adverse reactions and patients should be monitored for the following: • Risks to Patients wit

  34. Slide 34: Important Safety Information about AZSTARYS

    33 Important Safety Information about AZSTARYS AZSTARYS (serdexmethylphenidate and dexmethylphenidate (serdexmethylphenidate and dexmethylphenidate capsules) capsules) WARNING: ABUSE, MISUSE, AND ADDICTION AZSTARYS has a high potential for abuse, misuse, which can lead to the development of a substa

  35. Slide 35: Important Safety Information about AZSTARYS

    34 Important Safety Information about AZSTARYS AZSTARYS (serdexmethylphenidate (serdexmethylphenidate and dexmethylphenidate capsules) and dexmethylphenidate capsules) WARNINGS AND PRECAUTIONS • Risks to patients with serious cardiac disease: Avoid use in patients with known structural cardiac abnor

  36. Slide 36: Important Safety Information about XTAMPZA ER

    35 Important Safety Information about XTAMPZA ER XTAMPZA ER (Oxycodone) extended-release (oxycodone) extended-release capsules capsules WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF XTAMPZA ER Addiction, Abuse, and Misuse Because the use of XTAMPZA ER exposes patients and other users to th

  37. Slide 37: Important Safety Information about XTAMPZA ER

    36 Important Safety Information about XTAMPZA ER XTAMPZA ER (Oxycodone) extended-release (oxycodone) extended-release capsules capsules Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to c

  38. Slide 38: Important Safety Information about BELBUCA

    37 Important Safety Information about BELBUCA BELBUCA (buprenorphine buccal (buprenorphine buccal film) film) WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BELBUCA Addiction, Abuse, and Misuse BELBUCA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, whi

  39. Slide 39: Important Safety Information about NUCYNTA ER

    38 Important Safety Information about NUCYNTA ER NUCYNTA ER (tapentadol) extended- (tapentadol) extended-release tablets release tablets WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF NUCYNTA ER Addiction, Abuse, and Misuse Because the use of NUCYNTA ER exposes patients and other users to t

  40. Slide 40: Important Safety Information about NUCYNTA ER

    39 Important Safety Information about NUCYNTA ER NUCYNTA ER (tapentadol) extended- (tapentadol) extended-release tablets release tablets Neonatal Opioid Withdrawal Syndrome If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may

  41. Slide 41: Important Safety Information about NUCYNTA

    40 Important Safety Information about NUCYNTA NUCYNTA (tapentadol) tablets (Tapentadol) tablets WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF NUCYNTA TABLETS Addiction, Abuse, and Misuse Because the use of NUCYNTA tablets exposes patients and other users to the risks of opioid addiction, a

  42. Slide 42: Important Safety Information about SYMPROIC

    41 Important Safety Information about SYMPROIC SYMPROIC (naldemedine) tablets (naldemedine) tablets SYMPROIC may cause serious side effects, including: – Tear in your stomach or intestinal wall (perforation). Stomach pain that is severe can be a sign of a serious medical condition. If you get stomac

  43. Slide 43: Important Safety Information about SYMPROIC

    42 Important Safety Information about SYMPROIC SYMPROIC (naldemedine) tablets (naldemedine) tablets INDICATIONS AND USAGE SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior

  44. Slide 44: Important Safety Information about SYMPROIC

    43 Important Safety Information about SYMPROIC SYMPROIC (naldemedine) tablets (naldemedine) tablets USE IN SPECIFIC POPULATIONS Pregnancy: There are no available data with Naldemedine in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. There is a potential for

  45. Slide 45: Non-GAAP Reconciliations

    Non-GAAP Reconciliations a <@O Collegium. PHARMACEUTICAL

  46. Slide 46: Reconciliation of GAAP Net Income to Adjusted EBITDA

    45 Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands, unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 2026 2025 GAAP net (loss) income $ 21,759 $ 31,507 $ 21,204 $ 45,907 Adjustments: Interest expense 21,943 21,767 57,324 63,020 Interest income

  47. Slide 47: Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses

    Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses 46 (in thousands, unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 2026 2025 GAAP operating expenses $ 96,696 $ 67,084 $ 289,640 $ 216,000 Adjustments: Stock-based compensation 12,445 9,811

  48. Slide 48: Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted EPS

    Reconciliation of GAAP Net Income to Adjusted Net Income and 47 Adjusted Earnings Per Share (in thousands, except share and per share amounts, unaudited) Three Months Ended September Nine Months Ended 30, September 30, 2026 2025 2026 2025 GAAP net (loss) income $ 21,759 $ 31,507 $ 21,204 $ 45,907 Ad

Collegium Pharmaceutical — Q3 2026 Earnings Presentation on 6ix